X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
17/11/2020
Professor Giuseppe Novelli (PhD) is Head of the Human Genetics Research Unit at The Tor Vergata University of Rome (Italy). He is Adjunct Professor at the University of Reno, Nevada (USA). He served for 5 years as member of the Pharmacogenetics Working Party, EMA (European Medicines Agency). He is actually member of the Italian National Committee for Biotechnology and Biosecurity of the Italian President of Council.
The primary focus in genetics of Prof. Novelli is the mapping, identification and characterization of human‑disease genes (e.g., Laron dwarfism, cystic fibrosis, DiGeorge syndrome, Mandibuloacral dysplasia, Friedrich ataxia vitamin-E-deficiency, myotonic dystrophy, psoriasis, galactosemia, hereditary nonspherocytic haemolytic anemia, atherosclerosis and myocardial infarction). One of the major interests of Prof. Novelli research is in the field of complex diseases. He identified the major loci involved in psoriasis identifying the genes implicated in the disease (published on Nature Genetics, Oct 2010) and in the atherosclerosis identifying an isoform (named loxin) of the LOX-1 receptor. He characterized this protein and established in part its biological role. Prof. Novelli demonstrated for the first time that a single nucleotide mutation in the LMNA gene is responsible of a progeroid syndrome, the mandibuloacral dysplasia (MAD) and suggest that this protein is actively involved in premature aging. The observation that mutations in the LMNA gene are responsible for premature aging has opened a new line of research called "laminopathies" which today includes more than 30 different diseases.
In the last 10 years Novelli’s lab developed original research on human stem cells, characterizing Human Cytotrophoblastic‑derived Multipotent Cells (hCTMCs) from Human Chorionic villi (CVS). These cells may be a safe and convenient source of cells for cell-based therapy, as well as an ideal target for in utero fetal gene therapy. They also developed a cancer stem cell model starting from normal human stem cells derived from amniotic and chorionic placenta membranes. These cells are able to differentiate into neural cell lineages and to undergo spontaneous transformations and acquire an NB-like phenotype. The acquisition of these technologies has allowed Prof. Novelli's laboratory to develop an advanced protocol to derive human induced pluripotent stem cells (hiPSCs) from patients affected by genetic diseases.
His contribution to cancer is documented by the identification and characterization of the human gene, DVL‑1, a Disheveled family member involved in Wnt signaling which governs several cellular processes including cell proliferation, survival, migration, differentiation, polarity and stem cell renewal; from the definition of the role of the OLR1 gene as oncogene by activation of NF-kB target genes responsible for proliferation, migration and inhibition of apoptosis and de novo lipogenesis genes, to the identification of mutations of the POLD1gene gene (DNA polymerase δ) in multisystem disorders. In addition, Prof. Novelli has been involved in pharmacogenetics and pharmacogenomics identifying new markers and developing innovative diagnostic technologies such as liquid biopsy for the characterization of mutations in different types of cancer.
Prof. Novelli is currently involved in Covid-19 host-genetics identifying for the first time life-threating mutations in genes coding for interferons (Zhang et al, Science, 2020).
Recommended Content
Share this post
Choose a social network to share with, or copy the shortened URL to share elsewhere

network.febs.org
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract.
Cookies
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Sign in or join for free to access this content
Sign in to FEBS Network
Join the FEBS Network today
Joining the FEBS Network’s molecular life sciences community enables you to access special content on the site, present your profile, 'follow' contributors, 'comment' on and 'like' content, post your own content, and set up a tailored email digest for updates.
Register